Product logins

Find logins to all Clarivate products below.


Moira Ringo

Director, Consulting

Moira comes to Clarivate with over 20 years of experience in healthcare industry and consulting, and focusses primarily on commercial strategy and market access. Moira began her career in GSK Research and Development after witnessing first-hand the power of medicine for a family member with cancer. At GSK she contributed to clinical development of over 20 assets, including the second approved personalized therapy for oncology. As she observed market access having an increasing role on product uptake, she transitioned to a role optimizing product strategy for newly launched and mature products at GSK, including supporting the launch of the first gene therapy for a rare disease.
Her consulting roles span US and global clinical, market access, and HEOR evidence strategy for advanced oncolytics, diagnostics, medical devices, and cell and gene therapies. She has developed robust channel, product, and market access strategies for the US market. Moira is passionate about uniting diverse client and consulting teams around the common goal of bringing science and technology to patients who need it.
Moira holds a PhD in chemistry from the University of Michigan and an MBA from the Duke Fuqua School of Business with a certificate in health sector management.


arrow_forward
Get in touch with Moira

Latest news

News July 10, 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026

London, U.K., July 10, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second…

News July 9, 2026
Clarivate Releases G20 Research and Innovation Scorecard 2026

Tracking global research power, impact and collaboration as G20 priorities shift

News July 6, 2026
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.